Myeloid Gene Panel
Requires patient informed consent
Test details
This next-generation sequencing (NGS) panel enables the analysis of 75 genes that are frequently mutated in myeloid malignancies. With its expanded gene coverage, plus identification of copy number variations (CNVs), the panel provides more detailed information than other panels as well as further genomic information.
The 75 genes are related to acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS). It also contains a number of targets that are related to lymphoid malignancies (acute lymphocytic leukemia, ALL, and lymphoma), and 23 of the genes are also targeted for the detection of CNVs.
Among the targets are Calreticulin (CALR), JAK2, MPL and NPM1, which were previously offered as individual tests.
| ABL1, ANKRD26, ASXL1, ATRX, BCOR, BCORL1, BRAF BTK, CALR, CBL, CBLB, CBLC, CCND2, CDKN2A, CEBPA, CSF3R, CUX1, CXCR4, DCK, DDX41,, DHX15, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MAP2K1, MPL, MYC, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RAD21, RBBP6, RUNX1, SETBP1, SF3B1, SH2B3, SLC29A1, SMC1A SMC3, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, U2AF2, WT1, XPO1, ZRSR2. |
| Myeloid gene panel (75 genes) |
|---|
Profile details
This is a 75 gene targeted NGS panel for acute myeloid leukaemia, myeloproliferative neoplasms, myelodysplastic syndromes, and also contains a number of targets which are useful for lymphoid malignancies (ALL and lymphoma). It uses Anchored Multiplex PCR (AMPTM) chemistry which enables deep strand-specific amplification of molecular barcoded DNA fragments for sequencing.
Code
MVPS
Sample Reqs
A (3mL minimum) or bone marrow aspirate sample
Turnaround
2 weeks
Special instructions
No special instructions.
Sample type guide
A
Lavender Vacutainer, EDTA anticoagulant, 4ml/6ml (6ml EDTA tubes are used for specific PCR assays)
Additional information